Brainsway Ltd ADR
Earnings Details
2nd Quarter June 2022
Wednesday, August 10, 2022 7:30:00 AM
Tweet Share Watch

Brainsway Ltd ADR (BWAY) Reports 2nd Quarter Earnings

Brainsway Ltd ADR (BWAY) reported a 2nd Quarter June 2022 loss of $0.07 per share on revenue of $8.0 million. The consensus estimate was a loss of $0.08 per share on revenue of $8.4 million. Revenue grew 14.3% on a year-over-year basis.

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction.

Reported Earnings
Earnings Whisper
Consensus Estimate
Reported Revenue
$8.0 Mil
Revenue Estimate
$8.4 Mil
Earnings Growth
Revenue Growth
Power Rating
Earnings Release

BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights

Revenue Growth of 14% Year-over-Year in Q2 2022

Conference call to be held today, August 10, 2022, at 8:30 AM ET

BURLINGTON, Mass. and JERUSALEM, Aug. 10, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported second quarter 2022 financial results and provided an operational update.

Recent Financial and Operational Highlights

  • For the three months ended June 30, 2022, revenues were $8.0 million, a 14% increase as compared to the prior year period.
  • As of June 30, 2022, BrainsWay’s Deep TMS™ installed base was 829 total systems, a 22% increase from the installed base at the same point in the prior year.
  • As of June 30, 2022, the Company had shipped 368 obsessive-compulsive disorder (OCD) coils as add-on helmets to certain of BrainsWay’s new and existing systems.
  • Cash, cash equivalents and short-term deposits as of June 30, 2022, amounted to $52.4 million, compared to $57.3 million as of December 31, 2021.
  • Announced that Highmark Blue Cross Blue Shield (BCBS), which covers 6.8 million members in the states of New York, Pennsylvania, West Virginia, and Delaware, and is the fourth largest BCBS health plan in the U.S., issued a positive coverage policy applicable to the BrainsWay Deep TMS system for the treatment of OCD, effective May 2, 2022.
  • Israeli Ministry of Health approved coverage applicable to Deep TMS for the treatment of depression.

“We recorded solid second quarter results, again reflecting the growing demand for our non-invasive therapy in multiple indications and markets, despite certain macroeconomic challenges impacting existing and potential new customers,” stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. “We generated $8.0 million in revenue for the second quarter of 2022, which represented a 14% increase as compared to the second quarter of 2021, our eighth consecutive quarter of year-over-year growth. These results are especially impressive as the team faced the realities of inflation and concerns over an economic recession in the U.S. from our customers and their patients.”

“We also continue to achieve important reimbursement progress, highlighted by the recent Highmark BCBS positive coverage policy in OCD that increased the total number of lives eligible for Deep TMS coverage in this indication to nearly 70 million.”  

“Given the increasing demand for mental healthcare, we believe that Deep TMS is well positioned to grow versus other non-invasive medical technology and pharmaceutical therapy options. With approved indications for Depression (including Anxious Depression), OCD, and Smoking Addiction, and data from 34 randomized clinical trials, many of which were placebo controlled, no other TMS therapy can equal the depth of the clinical evidence reinforcing the significant benefits of our Deep TMS system,” concluded Dr. von Jako.

Second Quarter 2022 Financial Results

  • Total revenues for the second quarter of 2022 were $8.0 million, compared to $7.0 million in the second quarter of 2021, an increase of 14%.
  • Gross margin for the second quarter of 2022 was 73%, compared to 81% for the second quarter 2021, largely attributable to expenses related to inventory obsolescence and a higher mix of international sales.
  • Operating expenses for the second quarter of 2022 totaled $7.8 million, compared to $7.2 million for the second quarter of 2021.
  • Operating loss for the second quarter of 2022 was $2.0 million, compared to a loss of $1.5 million for the same period in 2021.

Conference Call and Webcast

BrainsWay’s management will host a conference call on Wednesday, August 10, 2022, at 8:30 a.m. Eastern Time to discuss these results and answer questions.

Wednesday, August 10, 2022, at 8:30 AM Eastern Time:

United States:1-877-407-3982
Conference ID:13731331

To listen to a live webcast, please visit the Investors section of the BrainsWay website at Please access the Company’s website at least 10 minutes ahead of the conference call to register. The webcast replay will be available on the website for two weeks following the completion of the call.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.

Scott Areglado
SVP and Chief Financial Officer

Bob Yedid
LifeSci Advisors


U.S. dollars in thousands
  June 30, December 31,
  2022 2021
ASSETS (Unaudited)
Current Assets        
Cash and cash equivalents $52,174  $16,921 
Short-term deposits  271   40,428 
Trade receivables, net  7,412   6,332 
Inventory  2,311   - 
Other current assets  1,557   1,766 
   63,725   65,447 
Non-Current Assets        
System components  2,458   4,463 
Leased systems, net  3,557   3,813 
Other property and equipment, net  1,019   1,055 
Other long-term assets  999   954 
   8,033   10,285 
  $71,758  $75,732 
Current Liabilities        
Trade payables $1,658  $1,102 
Deferred revenue  1,972   2,195 
Liability in respect of research and development grants  1,011   978 
Other accounts payable  3,625   4,792 
   8,266   9,067 
Non-Current Liabilities        
Deferred revenue and other liabilities  3,883   3,419 
Liability in respect of research and development grants  5,946   5,921 
   9,829   9,340 
Share capital  363   363 
Share premium  137,904   137,566 
Share-based payment reserve  5,783   5,340 
Currency Translation Adjustments  (2,188)  (2,188)
Accumulated deficit  (88,199)  (83,756)
   53,663   57,325 
  $71,758  $75,732 


U.S. dollars in thousands (except per share data)
  For the three months ended June 30, For the six months ended June 30,
   2022   2021   2022   2021 
  (Unaudited) (Unaudited)
Revenues $8,006  $7,005  $15,976  $13,126 
Cost of revenues  2,192   1,300   4,059   2,763 
Gross profit  5,814   5,705   11,917   10,363 
Research and development expenses, net  1,731   1,650   3,307   2,575 
Selling and marketing expenses  4,552   4,191   8,698   7,320 
General and administrative expenses  1,539   1,377   3,402   2,782 
Total operating expenses  7,822   7,218   15,407   12,677 
Operating loss  (2,008)  (1,513)  (3,490)  (2,314)
Finance expense, net  (329)  (269)  (653)  (681)
Loss before income taxes  (2,337)  (1,782)  (4,143)  (2,995)
Income taxes  113   156   300   316 
Net loss and total comprehensive loss $(2,450) $(1,938) $(4,443) $(3,311)
Basic and diluted net loss per share $(0.07) $(0.06) $(0.13) $(0.11)

U.S. dollars in thousands
  For the three months ended June 30, For the six months ended June 30,
   2022   2021   2022   2021 
  (Unaudited) (Unaudited)
Cash flows from operating activities:        
Total comprehensive loss $(2,450) $(1,938) $(4,443) $(3,311)
Adjustments to reconcile net loss to net cash used in operating activities:        
Adjustments to profit or loss items:        
Depreciation and amortization  154   131   296   281 
Depreciation of leased systems  246   288   491   580 
Impairments and disposals  301   227   233   480 
Finance expenses, net  329   269   653   681 
Cost of share based payment  408   280   782   1,083 
Income taxes  113   156   300   316 
Total adjustments to reconcile loss  1,551   1,351   2,755   3,421 
Changes in asset and liability items:        
Increase in trade receivables  (1,072)  (38)  (1,135)  (1,131)
Increase in inventory  (792)  -   (2,105)  - 
Decrease in other accounts receivable  (257)  (1,017)  (318)  (999)
Increase (decrease) in trade payables  1,073   (377)  561   (86)
Increase (decrease) in other accounts payable  (384)  12   (894)  (200)
Increase (decrease) in deferred revenues and other liabilities  (5)  50   268   212 
Total changes in asset and liability  (1,437)  (1,370)  (3,623)  (2,204)
Cash paid and received during the period for:        
Interest paid  (11)  (10)  (23)  (30)
Interest received  304   -   307   2 
Income taxes paid  (263)  148   (266)  (12)
Total cash paid and received during the period  30   138   18   (40)
Net cash used in operating activities:  (2,306)  (1,819)  (5,293)  (2,134)
Cash flows from investing activities:        
Proceeds from (purchase of) property and equipment and system components, net  448   (538)  1,399   (917)
Investment in short-term deposits, net  40,304   (40,000)  40,254   (40,000)
Investment in long-term deposits, net  (2)  (11)  (5)  (11)
Net cash provided by (used in) investing activities  40,750   (40,549)  41,648   (40,928)
Cash flows from financing activities:        
Repayment of liability in respect of research and development grants  -   (373)  (498)  (373)
Receipt of government grants  -   77   6   167 
Repayment of lease liability  (150)  (227)  (298)  (227)
Issuance of share capital, net  -   -   1   42,260 
Net cash provided by (used in) financing activities  (150)  (523)  (789)  41,827 
Exchange rate differences on cash and cash equivalents  (225)  207   (313)  (130)
Increase (decrease) in cash and cash equivalents  38,069   (42,684)  35,253   (1,365)
Cash and cash equivalents at the beginning of the period  14,105   58,280   16,921   16,961 
Cash and cash equivalents at the end of the period $52,174  $15,596  $52,174  $15,596 
(a) Significant non cash transactions:        
Recognition of new lease liability and right-of-use  123   -   123   183 


Primary Logo

Source: BrainsWay